DellingerRP, LevyMM, CarletJMet al. International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med, 2008; 36:296–327Erratum in: Crit Care Med 2008;36:1394–1396.
2.
BariePS, HydoLJ, ShouJet al.Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg Infect (Larchmt), 2005; 6:41–54.
3.
BariePS, HydoLJ, FischerE. Comparison of APACHE II and III scoring systems for mortality prediction in critical surgical illness. Arch Surg, 1995; 130:77–82.
BariePS. “All in” for a huge pot: the PROWESS-SHOCK trial for refractory septic shock. Surg Infect (larchmt), 2007Oct8,5:491–494.
6.
FinferS, RanieriVM, ThompsonBTet al.Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med, 2008; 34:1935–1947Erratum in: Intensive Care Med 2011;37:372.
7.
BernardGR, VincentJL, LaterrePFet al.Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 2001; 344:699–709.
8.
TalmorM, HydoL, BariePS. Relationship of systemic inflammatory response syndrome to organ dysfunction, length of stay, and mortality in critical surgical illness: Effect of intensive care unit resuscitation. Arch Surg, 1999; 134:81–87.
9.
BariePS, HydoLJ, ShouJ, EachempatiSR. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome. Surg Infect, 2011; 12:443–449.
10.
RussellJA, WalleyKR, SingerJet al.VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med, 2008; 28,358:877–887.
11.
SprungCL, AnnaneD, KehDet al.CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med, 2008; 358:111–124.
12.
ThompsonBT, RanieriVM, FinferSet al.Statistical analysis plan of PROWESS SHOCK study. PROWESS SHOCK Steering Committee. Intensive Care Med., 2010; 36:1972–1973.
13.
RanieriVM, ThompsonBT, FinferSet al.Unblinding plan of PROWESS-SHOCK trial. PROWESS-SHOCK Academic Steering Committee. Intensive Care Med, 2011; 37:1384–1385.
14.
BariePS. An opinion too far–the campaign against the Surviving Sepsis Campaign. Surg Infect (Larchmt), 2006; 7:485–488.
15.
BariePS. Current role of activated protein C therapy for severe sepsis and septic shock. Curr Infect Dis Rep, 2008; 10:368–376.
16.
AbrahamE, LaterrePF, GargRet al.Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med, 2005; 353:1332–1341.
